Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Core Insights - Traws Pharma has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, allowing its common stock to continue trading on The NASDAQ Capital Market under the symbol "TRAW" [1][3] - The company is advancing its pipeline of investigational antivirals, particularly focusing on bird flu and influenza, with a recent successful Phase 1 trial [2][4] - Traws Pharma raised$20 million in gross proceeds through a successful offering, strengthening its financial position [3] Company Overview - Traws Pharma is a clinical-stage biopharmaceutical company developing oral small molecule therapies for respiratory viral diseases, including two novel drug candidates: tivoxavir marboxil for bird/pandemic flu and seasonal flu, and ratutrelvir for COVID-19 [4][5] - The company aims to address unmet medical needs using advanced drug development technology, focusing on product safety and solutions for vulnerable patient populations [5]